Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

To evaluate the cross-resistance profile of the human immunodeficiency virus type 1 protease inhibitor (PI) atazanavir (BMS-232632), a panel of 551 clinical isolates exhibiting a wide array of PI resistance profiles and a variety of genotypic patterns were assayed for susceptibility to atazanavir an...

Description complète

Détails bibliographiques

Publié dans:	Antimicrob Agents Chemother
Auteurs principaux:	Colonno, Richard J., Thiry, Alexandra, Limoli, Kay, Parkin, Neil
Format:	Artigo
Langue:	Inglês
Publié:	American Society for Microbiology (ASM) 2003
Sujets:	Antiviral Agents
Accès en ligne:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC152527/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12654666/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.4.1324-1333.2003
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!